logo
Prediction: Buying This AI Stock Will Not Look Smart in 5 Years

Prediction: Buying This AI Stock Will Not Look Smart in 5 Years

Yahoo20 hours ago

C3.ai is growing its revenue at a decent rate, but it's not scaling its business with any efficiency.
It is growing slower than its AI peers and is posting huge operating losses.
The stock trades at an expensive valuation.
10 stocks we like better than C3.ai ›
Just about every stock with some connection to artificial intelligence (AI) has seen its price soar in the past couple of years. Ever stock, that is, except C3.ai (NYSE: AI), that is. The AI-focused company with the ticker "AI" is trading down around 22% over the past year and around 86% from all-time highs as the company struggles to grow and get anywhere close to generating a profit.
This AI company has a lot of hype around it, and even brags about huge wins with partnerships with other AI players. A lot of this is all bark and no bite.
Here's why investors will be disappointed with the results of C3.ai stock compared to other AI-associated investments over the next five years.
C3.ai has been a trendy name in the AI space for years. The company brands itself as the AI enterprise software company, deploying software solutions including its new agentic AI platform and generative AI tools. It has large customers, including energy giants and the U.S. Air Force, implementing its software in operations.
This all sounds fine and dandy, but it oversells C3.ai as a company with actual software products. Similar to a consultant, C3.ai has a large sales team that wins contracts to build custom software solutions for companies, which is different than a software provider that builds once and ships as many times as it can, such as Microsoft. It is a much more difficult business model, and one that is harder to scale with large profit margins. C3.ai generated only $389 million in revenue over the last 12 months, even though the AI sector is in the middle of one of the largest spending booms ever.
Compare that to its quasi-competitor, Palantir Technologies. The company generated $3.11 billion in revenue over the last 12 months and is growing revenue much faster than C3.ai. Last quarter, C3.ai's revenue grew 26% year over year compared to 39% for Palantir.
One could argue, looking at the metrics referenced above, that C3.ai is in fine shape as a business. It is growing revenue at over 20% year over year and has long-term software consultant contracts with big enterprises. But those strong top-line metrics aren't making it down to the company's bottom-line profit and loss metrics, which keep moving in the wrong direction. This is an indicator that the company has a bloated expense structure and will struggle to scale due to the custom-built software it deploys.
Last fiscal year, C3.ai had an operating loss of $324 million on $389 million in revenue. It spent $231 million on stock-based compensation -- a noncash dilutive expense -- which is around 60% of its overall revenue. This is an unsustainable figure and needs to be dramatically reduced in order for C3.ai to generate a profit. Spending 10% of revenue on stock-based compensation can be a concern for investors when analyzing a stock, but 60% is unheard of.
It is no surprise then why C3.ai stock is down. It has to spend a boatload every year to retain its research, sales, and operational staff that deploy these consultant contracts with large enterprises, and these costs are simply outweighing any revenue earned by these contracts, making C3.ai persistently unprofitable.
Two main reasons stand out to me as to why C3.ai stock will struggle to generate a positive return for shareholders over the next five years. First, the services it provides do not look scalable due to the custom-build process and heavy losses it is sustaining. In fact, it looks like the company has the opposite of operating leverage, as its operating loss has gotten worse and worse since going public around five years ago, even though revenue is growing.
Second, C3.ai stock trades at a high valuation. It has a price-to-sales (P/S) ratio of 8.5, which is much higher than the S&P 500 average. This is for a company with deeply negative operating margins and no history of profitability. Yes, revenue is growing at a decent clip, but the company is showing zero signs of operating leverage. In fact, one might argue that growing revenue is a bad thing for C3.ai, as historically, all growing revenue has done is lead to larger operating losses.
A high valuation, huge losses, and slower revenue growth than its AI peers make C3.ai a bad stock to own right now. Avoid buying it for your portfolio despite the AI hype in the markets today.
Before you buy stock in C3.ai, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and C3.ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!*
Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Microsoft and Palantir Technologies. The Motley Fool recommends C3.ai and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Prediction: Buying This AI Stock Will Not Look Smart in 5 Years was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Prediction: This Red-Hot Growth Stock Will Continue Soaring in the Second Half of 2025
Prediction: This Red-Hot Growth Stock Will Continue Soaring in the Second Half of 2025

Yahoo

time34 minutes ago

  • Yahoo

Prediction: This Red-Hot Growth Stock Will Continue Soaring in the Second Half of 2025

Broadcom is an excellent way to invest in global connectivity and AI. The stock is within a few percentage points of making a new all-time high. Broadcom is benefiting from sustained capital expenditure investments in AI from key customers. 10 stocks we like better than Broadcom › The "Magnificent Seven" gets a lot of attention -- and rightfully so -- as its components, Microsoft, Nvidia, Apple, Alphabet, Amazon, Meta Platforms, and Tesla, have all produced massive gains in recent years and life-changing gains over the long term. But if there were a Magnificent Eight, Broadcom (NASDAQ: AVGO) would be the most deserving addition. The semiconductor giant sports a market cap of $1.2 trillion and has produced a mind-numbing 373% gain in just the last three years and is up 772% in the last five years. If there were a Magnificent Eight, Broadcom would be the second-best performer during the last three to five years -- behind only Nvidia. Here's why Broadcom has what it takes to continue soaring in the second half of 2025 and beyond. Broadcom's value has compounded so much in recent years because the company is an industry leader in global connectivity and benefits from growth in artificial intelligence (AI). Broadcom operates in several end markets, including cloud infrastructure, networking, cybersecurity, storage, broadband, wireless, and even solutions for hyperscale data centers. Its acquisition of VMware in late 2023 boosted Broadcom's exposure to infrastructure software. Broadcom's core business (including VMware) is a stable, consistent cash cow. But what's really driving investor excitement is likely Broadcom's AI business. In Broadcom's most recent quarter, which was second-quarter fiscal 2025, consolidated revenue grew 20% year over year, but AI semiconductor revenue jumped 46% to $4.4 billion -- representing 29% of total revenue. For context, Broadcom's AI revenue made up 25% of total revenue a year ago. So, the overall business is growing at an excellent pace, but AI is growing even faster. One of Broadcom's key AI products is its application-specific integrated circuits (ASICs). ASICS are AI chips for data centers that can be lower-cost alternatives to graphics processing units (GPUs) because they can perform a specific function really well. In contrast, GPUs are basically catch-all workhorses for AI workflows. Broadcom's XPUs are custom ASIC chips designed for AI workloads. On its March earnings call, Broadcom said that it believes the serviceable addressable market for these chips will grow to $90 billion by fiscal 2027 as hyperscale customers go from clusters of 500,000 accelerators to 1 million accelerators. These larger clusters could potentially boost efficiency and performance, which would be a net benefit for cloud service providers. Fast-forward three months on its latest earnings call, and Broadcom said that it continues to expect a great deal of AI accelerator clusters to use its XPUs. It also expects AI semiconductor revenue in the current quarter to skyrocket to $5.1 billion, a 60% increase compared to third-quarter fiscal 2024. Another element of Broadcom's AI revenue is AI networking, led by Ethernet, which represented 40% of AI revenue in the recent quarter. Broadcom offers a comprehensive portfolio of AI networking tools such as routers, switches, and controllers. These tools can work hand-in-hand with servers, GPUs, and AI accelerators (like XPUs) to drive AI training and deployment. All told, Broadcom is well positioned to capture AI investment through its networking tools and its XPU chips. Meanwhile, the core business continues to deliver exceptional results. Broadcom is an excellent stock to buy and hold for investors who believe in sustained AI spending. Despite tariff pressure and geopolitical uncertainty, the vast majority of big tech companies and hyperscalers (many of which are Broadcom customers) didn't change their capital expenditure forecasts when they reported earnings in April and early May. And if anything, some companies even raised their capex forecasts -- a sign that AI spending wasn't phased by trade tensions. It's also worth mentioning that many of these big tech companies have exceptional balance sheets, allowing them to invest throughout the business cycle and limit boom and bust periods of spending. Broadcom is an impeccable business with growth opportunities across various end markets, including AI. But the stock is far from cheap -- sporting a forward price-to-earnings ratio of 38.7 -- which is even higher than Nvidia at 33.9. However, Broadcom is less of a pure-play company than Nvidia, which makes the vast majority of its earnings from GPUs for data centers. Broadcom also has a stable and growing dividend -- which it has raised for 15 consecutive years. Even near an all-time high, Broadcom is worth a closer look for investors looking for a balanced tech company that benefits from AI but isn't solely dependent on AI to drive earnings growth. Although Broadcom could continue soaring in the second half of this year, it must continue delivering exceptional earnings growth to justify its expensive valuation. So, the best way to approach the stock is with at least a three- to five-year investment time horizon rather than hoping for quarterly outperformance. Before you buy stock in Broadcom, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Broadcom wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Daniel Foelber has positions in Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Prediction: This Red-Hot Growth Stock Will Continue Soaring in the Second Half of 2025 was originally published by The Motley Fool

Oxford Instruments Full Year 2025 Earnings: EPS Misses Expectations
Oxford Instruments Full Year 2025 Earnings: EPS Misses Expectations

Yahoo

timean hour ago

  • Yahoo

Oxford Instruments Full Year 2025 Earnings: EPS Misses Expectations

Revenue: UK£500.6m (up 6.4% from FY 2024). Net income: UK£26.0m (down 49% from FY 2024). Profit margin: 5.2% (down from 11% in FY 2024). The decrease in margin was driven by higher expenses. EPS: UK£0.45 (down from UK£0.88 in FY 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 56%. The primary driver behind last 12 months revenue was the Imaging & Analysis segment contributing a total revenue of UK£330.5m (66% of total revenue). The largest operating expense was General & Administrative costs, amounting to UK£98.4m (42% of total expenses). Explore how OXIG's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 5.5% growth forecast for the Electronic industry in the United Kingdom. Performance of the British Electronic industry. The company's share price is broadly unchanged from a week ago. Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Oxford Instruments that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Business Wire

timean hour ago

  • Business Wire

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs.' 'Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,' said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. 'This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes.' About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN N.V. Category: Precision Medicine

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store